385 related articles for article (PubMed ID: 25466251)
21. Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome.
Lovelace JW; Rais M; Palacios AR; Shuai XS; Bishay S; Popa O; Pirbhoy PS; Binder DK; Nelson DL; Ethell IM; Razak KA
Cereb Cortex; 2020 Mar; 30(3):969-988. PubMed ID: 31364704
[TBL] [Abstract][Full Text] [Related]
22. Delayed stabilization of dendritic spines in fragile X mice.
Cruz-Martín A; Crespo M; Portera-Cailliau C
J Neurosci; 2010 Jun; 30(23):7793-803. PubMed ID: 20534828
[TBL] [Abstract][Full Text] [Related]
23. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
[TBL] [Abstract][Full Text] [Related]
24. Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.
Higashimori H; Schin CS; Chiang MS; Morel L; Shoneye TA; Nelson DL; Yang Y
J Neurosci; 2016 Jul; 36(27):7079-94. PubMed ID: 27383586
[TBL] [Abstract][Full Text] [Related]
25. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice.
Hayashi ML; Rao BS; Seo JS; Choi HS; Dolan BM; Choi SY; Chattarji S; Tonegawa S
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11489-94. PubMed ID: 17592139
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2.
Aguilar-Valles A; Matta-Camacho E; Khoutorsky A; Gkogkas C; Nader K; Lacaille JC; Sonenberg N
J Neurosci; 2015 Aug; 35(31):11125-32. PubMed ID: 26245973
[TBL] [Abstract][Full Text] [Related]
28. Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse.
Higashimori H; Morel L; Huth J; Lindemann L; Dulla C; Taylor A; Freeman M; Yang Y
Hum Mol Genet; 2013 May; 22(10):2041-54. PubMed ID: 23396537
[TBL] [Abstract][Full Text] [Related]
29. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
Berry-Kravis E
Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
[TBL] [Abstract][Full Text] [Related]
30. Dysregulation of mTOR signaling in fragile X syndrome.
Sharma A; Hoeffer CA; Takayasu Y; Miyawaki T; McBride SM; Klann E; Zukin RS
J Neurosci; 2010 Jan; 30(2):694-702. PubMed ID: 20071534
[TBL] [Abstract][Full Text] [Related]
31. Astrocytic Contributions to Synaptic and Learning Abnormalities in a Mouse Model of Fragile X Syndrome.
Hodges JL; Yu X; Gilmore A; Bennett H; Tjia M; Perna JF; Chen CC; Li X; Lu J; Zuo Y
Biol Psychiatry; 2017 Jul; 82(2):139-149. PubMed ID: 27865451
[TBL] [Abstract][Full Text] [Related]
32. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Dolan BM; Duron SG; Campbell DA; Vollrath B; Shankaranarayana Rao BS; Ko HY; Lin GG; Govindarajan A; Choi SY; Tonegawa S
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5671-6. PubMed ID: 23509247
[TBL] [Abstract][Full Text] [Related]
33. Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice.
Aryal S; Longo F; Klann E
Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33906942
[TBL] [Abstract][Full Text] [Related]
34. BDNF in fragile X syndrome.
Castrén ML; Castrén E
Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
[TBL] [Abstract][Full Text] [Related]
35. Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome.
Jawaid S; Kidd GJ; Wang J; Swetlik C; Dutta R; Trapp BD
Glia; 2018 Apr; 66(4):789-800. PubMed ID: 29274095
[TBL] [Abstract][Full Text] [Related]
36. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.
Siller SS; Broadie K
Dis Model Mech; 2011 Sep; 4(5):673-85. PubMed ID: 21669931
[TBL] [Abstract][Full Text] [Related]
37. A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice.
Shukla T; de la Peña JB; Perish JM; Ploski JE; Stumpf CR; Webster KR; Thorn CA; Campbell ZT
Neurotherapeutics; 2021 Jan; 18(1):624-639. PubMed ID: 33006091
[TBL] [Abstract][Full Text] [Related]
38. Fragile X: leading the way for targeted treatments in autism.
Wang LW; Berry-Kravis E; Hagerman RJ
Neurotherapeutics; 2010 Jul; 7(3):264-74. PubMed ID: 20643379
[TBL] [Abstract][Full Text] [Related]
39. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
[TBL] [Abstract][Full Text] [Related]
40. Disruption of GpI mGluR-Dependent Cav2.3 Translation in a Mouse Model of Fragile X Syndrome.
Gray EE; Murphy JG; Liu Y; Trang I; Tabor GT; Lin L; Hoffman DA
J Neurosci; 2019 Sep; 39(38):7453-7464. PubMed ID: 31350260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
